WeForNews | Latest News, Breaking News, News Updates Domestic passengers landing at Kerala don't seem to need Aarogya Setu | WeForNews | Latest News, Blogs
Connect with us

Health

Domestic passengers landing at Kerala don’t seem to need Aarogya Setu

After landing at the airport here, all were asked to pass through a thermal scanner.

Published

on

Pinarayi Vijayan

Thiruvananthapuram, May 25 : With the commercial domestic aviation services restarting in the country on Monday, it appears the Aarogya Setu app is not a requirement at the Thiruvananthapuram airport.

A passenger who arrived from Delhi on the first flight that landed here on Monday told IANS that no one asked him about Aarogya Setu app inside or outside the airport here.

“When I entered the Delhi airport, I was asked if I have Aarogya Setu app and I said yes. Then I was allowed to enter the airport. In the aircraft what I could see was social distancing was maintained. There was no in-flight service of any sort during the flight,” said the passenger who did not wished to be identified.

After landing at the airport here, all were asked to pass through a thermal scanner.

“After that there is a health desk with a doctor and a few others. They asked me a few questions and I was let off as I had no symptoms. Then I had to fill a few forms and then went to a counter where I showed the pass that I had received when I first registered online two days back, before I booked my air ticket. The person manning the counter asked me all my details of where I will be staying and such things. After the registration was over, I got another pass and was allowed to go out of the airport,” said the passenger and added no one asked him about the app.

“Outside I could see buses of the state-owned Transport Department and I took a car and reached my home, where I have been asked to be in quarantine for 14 days. Now I will be staying indoors till my quarantine period is over,” added the passenger who works in Delhi.

According to rules here, anyone arriving in Kerala on flights, can go into state run quarantine centres, if they so wish or if they have a separate attached bathroom at their home can remain in it for two weeks, when the quarantine period will end.

Health

Natural antioxidants can keep heart, cancer diseases at bay

Published

on

By

Natural
File Photo

If you want to keep your immune system strong for fighting cardiovascular diseases or cancer, start taking natural antioxidants as health experts on Sunday stressed that it helps in improving overall health by providing many other health benefits.

According to experts, antioxidants are substances that may protect your cells against free radicals, which play a role in heart disease, cancer and other diseases.

Free radicals are molecules produced when your body breaks down food or when you’re exposed to tobacco smoke or radiation.

The latest antioxidant which is produced for the first time in India is gamma oryzanol, which is very quickly gaining popularity as a super antioxidant.

It is a substance that is taken out of rice bran oil. It is also found in wheat bran and some fruits and vegetables.

The experts said that gamma oryzanol is used for high cholesterol, symptoms of menopause and many other conditions.

“Gamma oryzanol is useful for controlling elevated cholesterol and triglyceride levels, supporting cardiovascular health along with controlling menopausal symptoms. Gamma oryzanol helps lower cholesterol because it helps decrease cholesterol absorption and increase cholesterol elimination. Along with this, it is also known to boost metabolic rate and may help with weight loss,” Swapna Chaturvedi, senior dietician, Department of Dietetics, AIIMS told IANS.

As gamma oryzanol is found to be effective in controlling high cholesterol level in the body, it is registered in Japan and the US as a natural medicine to treat hyperlipidemia/dyslipidaemia (elevated cholesterol levels/unhealthy cholesterol levels.

Most research shows that taking natural antioxidants decreases total cholesterol, “bad” low-density lipoprotein (LDL) cholesterol, and blood fats called triglycerides in people with high cholesterol.

“It also helps in preventing heart attack by preventing platelet aggregation, a system where platelets blood gets stuck together and form clots that block arteries,” said Praveen Chandra, Head of Department, Interventional Cardiology, Medanta, The Medicity in Gurugram.

The experts mentioned that gamma oryzanol is also used for increasing testosterone and human growth hormone levels, as well as improving strength during resistance exercise training.

Gamma oryzanol also helps to inhibit different cancers in the body and builds immunity to fight cancer cells.

“Many of the antioxidants have proven beneficial in inhibiting the cancers at various stages. Gamma oryzanol has been found out to be effective antioxidant which comes from rice bran and helps in preventing cancer if taken for a long period,” said Rahul Bhargava, Director, Institute of Blood Disorder and BMT, Fortis Hospital, New Delhi.

Gamma oryzanol is basically activator of NK cells which gives the cancer cells a check.

It not only works through NK cells but also inhibits angiogenesis. It means it cuts the supply for the cancer cells to grow and increases your body’s own immunity to gather the strength to kill cancers.

“Gamma oryzanol also prevents cancers and studies show it helps in regressing the prostate cancer cells,” Bhargava noted.

Continue Reading

Health

No benefit from arthritis drug for severe Covid patients: Study

Published

on

By

File Photo

Contrary to a few studies that earlier suggested benefits from an arthritis drug for patients with severe or critical Covid-19 infection, a new study indicates that it is not better than standard care alone.

According to the researchers, including Regis G Rosa from Hospital Moinhos de Vento in Brazil, there was an increased number of deaths at 15 days in patients receiving an arthritis drug — tocilizumab — that resulted in the trial being stopped early.

These results contradict earlier observational studies suggesting benefit from tocilizumab. However, observational effects are limited by a high risk that they may be due to other unknown (confounding) factors — and some studies have not yet been peer reviewed or published in a medical journal, the researchers said in a paper published in The BMJ journal.

Tocilizumab blocks a specific part of the immune system (interleukin 6) that can go into overdrive in some patients with Covid-19.

According to the team, doctors think this might help lessen the body’s inflammatory response to the virus and avert some of the more dire consequences of the disease, but its effects are not well defined.

To test this theory, researchers conducted a randomised controlled trial involving 129 Covid-19 patients with an average age of 57 years and compared tocilizumab plus standard care with standard care alone.

Patients were receiving supplemental oxygen or mechanical ventilation and had abnormal levels of at least two chemicals linked to inflammation in their blood.

The study participants were randomly divided into two groups — 65 received tocilizumab plus standard care and 64 received standard care alone. All patients were monitored for 15 days.

By day 15, 18 (28 per cent) patients in the tocilizumab group and 13 (20 per cent) in the standard care group were receiving mechanical ventilation or had died.

Death at 15 days occurred in 11 (17 per cent) patients in the tocilizumab group compared with 2 (3 per cent) in the standard care group.

Continue Reading

Blog

Male sex hormones may help treat breast cancer: Study

While endocrine therapy is standard-of-care for estrogen receptor positive breast cancer, resistance to these drugs is the major cause of breast cancer mortality.

Published

on

By

breast cancer

Sydney : Researchers have found new evidence about the positive role of androgens, commonly thought of as male sex hormones but also found at lower levels in women, in breast cancer treatment.

In normal breast development, estrogen stimulates and androgen inhibits growth at puberty and throughout adult life.

Abnormal estrogen activity is responsible for the majority of breast cancers, but the role of androgen activity in this disease has been controversial.

The new research published in the journal Nature Medicine showed that androgens have potential for treatment of estrogen receptor positive breast cancer.

A cancer is called estrogen receptor positive if it has receptors for estrogen, according to Breastcancer.org.

Using cell-line and patient-derived models, the global team, including researchers at the University of Adelaide and the Garvan Institute of Medical Research in Australia, demonstrated that androgen receptor activation by natural androgen or a new androgenic drug had potent anti-tumour activity in all estrogen receptor positive breast cancers, even those resistant to current standard-of-care treatments.

In contrast, androgen receptor inhibitors had no effect.

“This work has immediate implications for women with metastatic estrogen receptor positive breast cancer, including those resistant to current forms of endocrine therapy,” said lead researcher Theresa Hickey, Associate Professor at the University of Adelaide.

“We provide compelling new experimental evidence that androgen receptor stimulating drugs can be more effective than existing (e.g. Tamoxifen) or new (e.g. Palbociclib) standard-of-care treatments and, in the case of the latter, can be combined to enhance growth inhibition,” said Wayne Tilley, Director of the Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide.

Androgens were historically used to treat breast cancer, but knowledge of hormone receptors in breast tissue was rudimentary at the time and the treatment’s efficacy misunderstood.

Androgen therapy was discontinued due to virilising side effects and the advent of anti-estrogenic endocrine therapies.

While endocrine therapy is standard-of-care for estrogen receptor positive breast cancer, resistance to these drugs is the major cause of breast cancer mortality.

“The new insights from this study should clarify the widespread confusion over the role of the androgen receptor in estrogen receptor driven breast cancer,” said Elgene Lim, a breast oncologist and Head of the Connie Johnson Breast Cancer Research Lab at the Garvan Institute.

“Given the efficacy of this treatment strategy at multiple stages of disease in our study, we hope to translate these findings into clinical trials as a new class of endocrine therapy for breast cancer.”

Continue Reading
Advertisement

Most Popular